Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38739
Title: | Updated Results of the COVID-19 in MS Global Data Sharing Initiative | Authors: | Simpson-Yap, Steve PIRMANI, Ashkan Kalincik, Tomas DE BROUWER, Edward GEYS, Lotte PARCIAK, Tina Helme, Anne Rijke, Nick Hillert, Jan A. Moreau, Yves Edan, Gilles Sharmin, Sifat Spelman, Tim McBurney, Robert Schmidt, Hollie Bergmann, Arnfin B. Braune, Stefan Stahmann, Alexander Middleton, Rod M. Salter, Amber Bebo, Bruce Van der Walt, Anneke Butzkueven, Helmut Ozakbas, Serkan Boz, Cavit Karabudak, Rana Alroughani, Raed Rojas, Juan I. van der Mei, Ingrid A. Sciascia do Olival, Guilherme Magyari, Melinda Alonso, Ricardo N. Nicholas, Richard S. Chertcoff, Anibal S. de Torres, Ana Zabalza Arrambide, Georgina Nag, Nupur Descamps, Annabel Costers, Lars Dobson, Ruth Miller, Aleisha Rodrigues, Paulo Prčkovska, Vesna Comi, Giancarlo PEETERS, Liesbet |
Issue Date: | 2022 | Publisher: | LIPPINCOTT WILLIAMS & WILKINS | Source: | Neurology-Neuroimmunology & Neuroinflammation, 9 (6) (Art N° e200021) | Abstract: | Background and Objectives Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed. Methods Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab. Results Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1–7] and 7% [95%CI 4–11]), ICU/artificial ventilation (2% [95% CI 0–4] and 4% [95% CI 2–6]), and death (1% [95% CI 0–2] and 2% [95% CI 1–4]) (predicted marginal effects). Untreated patients had 5% (95%CI2–8),3%(95%CI1–5),and1%(95%CI0–3)higherprobabilitiesofthe3respectivelevels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19. Discussion Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 medication (both ocrelizumab and rituximab), as well as male sex, older age, progressive MS, and higher disability are associated with more severe course of COVID-19. | Keywords: | Antigens, CD20;Glatiramer Acetate;Humans;Immunosuppressive Agents;Information Dissemination;Male;Natalizumab;Risk Factors;Rituximab;COVID-19;Multiple Sclerosis;Multiple Sclerosis, Chronic Progressive | Document URI: | http://hdl.handle.net/1942/38739 | ISSN: | 2332-7812 | e-ISSN: | 2332-7812 | DOI: | 10.1212/NXI.0000000000200021 | ISI #: | 000874687300009 | Rights: | 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open-access article distributed under the terms of the CreativeCommonsAttribution-NonCommercial-NoDerivativesLicense4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
e200021.full.pdf | Published version | 591.06 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.